Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05709444 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
A Phase 2 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05709444 is a Phase 2 study that has completed, run by Palatin Technologies. The registered enrollment target is 16 participants.
The verdict
NCT05709444, a Phase 2 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.
Interventions
- DRUG Bremelanotide
- DRUG RAAS inhibition therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-12-26 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05709444
The ClinicalTrials.gov registry entry for NCT05709444 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bremelanotide is the first listed.
NCT05709444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05709444 about?
NCT05709444 is a clinical study titled "A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease". This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for furthe...
What is the current status of trial NCT05709444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-12-26. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT05709444?
The interventions under investigation include: Bremelanotide (DRUG), RAAS inhibition therapy (DRUG).
Who is sponsoring clinical trial NCT05709444?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.